Niagen Bioscience Inc., formerly ChromaDex, is a global bioscience company uncovering the potential of NAD+ with precision science. Led by world-renowned scientists working with global research institutions to pioneer research on nicotinamide adenine dinucleotide (NAD+), our company officially changed its name from ChromaDex to Niagen Bioscience, effective March 19, 2025, with our NASDAQ ticker symbol changing from "CDXC" to "NAGE."
NAD+ is an essential coenzyme, present in all living cells, and is fundamental to mitochondrial bioenergetics, metabolic homeostasis, and genomic stability. Research shows NAD+ levels decline with age and metabolic stress, correlating with diminished cellular function and physiological resilience.
Distinguished by uncompromising scientific standards over 25 years since its inception, the company developed patented Niagen® (nicotinamide riboside, NR), which demonstrates superior efficacy compared to other NAD+ precursors in clinical trials. This proprietary compound powers evidence-based NAD+ enhancement solutions offered by our brands: pharmaceutical-grade intravenous (Niagen IV) and injectable formulations from Niagen® Plus, and high-bioavailability oral supplements from Tru Niagen®.
Our comprehensive intellectual property portfolio safeguards these innovations while we continue to advance the scientific understanding of NAD+ metabolism and its implications for human health and healthy aging.